Comorbidity index for predicting mortality at 6 months after reperfusion therapy

The eligibility of reperfusion therapy has been expanded to increase the number of patients. However, it remains unclear the reperfusion therapy will be beneficial in stroke patients with various comorbidities. We developed a reperfusion comorbidity index for predicting 6-month mortality in patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2021-03, Vol.11 (1), p.5963-9, Article 5963
Hauptverfasser: Nam, Hyo Suk, Kim, Young Dae, Yoo, Joonsang, Park, Hyungjong, Kim, Byung Moon, Bang, Oh Young, Kim, Hyeon Chang, Han, Euna, Kim, Dong Joon, Heo, Joonyung, Kim, Minyoung, Choi, Jin Kyo, Lee, Kyung-Yul, Lee, Hye Sun, Shin, Dong Hoon, Choi, Hye-Yeon, Sohn, Sung-Il, Hong, Jeong-Ho, Lee, Jong Yun, Baek, Jang-Hyun, Kim, Gyu Sik, Seo, Woo-Keun, Chung, Jong-Won, Kim, Seo Hyun, Song, Tae-Jin, Han, Sang Won, Park, Joong Hyun, Kim, Jinkwon, Jung, Yo Han, Cho, Han-Jin, Ahn, Seong Hwan, Lee, Sung Ik, Seo, Kwon-Duk, Heo, Ji Hoe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The eligibility of reperfusion therapy has been expanded to increase the number of patients. However, it remains unclear the reperfusion therapy will be beneficial in stroke patients with various comorbidities. We developed a reperfusion comorbidity index for predicting 6-month mortality in patients with acute stroke receiving reperfusion therapy. The 19 comorbidities included in the Charlson comorbidity index were adopted and modified. We developed a statistical model and it was validated using data from a prospective cohort. Among 1026 patients in the retrospective nationwide reperfusion therapy registry, 845 (82.3%) had at least one comorbidity. As the number of comorbidities increased, the likelihood of mortality within 6 months also increased ( p  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-85390-4